Clinical trial · Interventional
Moderate Hypofractionated Radiotherapy for Lung Cancer
Moderate Hypofractionated(3Gy/f) Radiotherapy for Advanced Lung Cancer: a Retrospective Study.
NCT03833193CI-TRIAL-00064931unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the incidences of Grade III and above radiation-reduced esophagitis and radiation-reduced pneumonia of patients with advanced lung cancer treated with moderate hypofractionated (3Gy/f) radiotherapy, and their predictors. Efficacies are also evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypofractionated radiotherapy
- description
- The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
- interventionNames
- Radiation: Hypofractionated radiotherapy
Primary outcomes (2)
- measure
- Incidence of grade III and above radiation-reduced esophagitis
- timeFrame
- three years
- description
- Incidence of grade III and above radiation-reduced esophagitis
- measure
- Incidence of grade III and above radiation-reduced pneumonitis
- timeFrame
- three years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with previously untreated advanced lung cancer were recruited, who were confirmed pathologically or cytologically. 2. The Karnofsky performance status (KPS) score ≥60. 3. The expected survival time was≥3 months. 4. The laboratory examination results showed a neutrophil count ≥2.0 × 109, a hemoglobin level ≥100 g/L, a platelet count ≥100 × 109, and enough liver and kidney functions. 5. The patients did not show abnormal electrocardiogram (ECG) results. 6. They did not have other combined diseases that required hospitalization. 7. Informed consent required before enrollment. Exclusion Criteria: 1. Patients who were pregnant or breastfeeding. 2. Patients who had another malignant tumor history (with the exception of patients with cervical carcinoma in situ and non-malignant melanoma skin cancer that had been clinically cured for at least 5 years), could not receive concurrent chemotherapy due to medical reasons. 3. Superior vena cava syndrome. 4. Syndrome and severe lung diseases that affected lung function were excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.